---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-036367"
form_type: "8-K"
ticker: "SANA"
cik: "0001770121"
company_name: "Sana Biotechnology, Inc."
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T14:54:57.793364+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Sana Biotechnology reports Q3 net loss $85.1M; cash $511.6M; pipeline IND timeline updates

## Summary
- Net loss of $85.1M ($0.45 per share) vs $83.3M ($0.46 per share) in Q3 2021; cash, cash equivalents and marketable securities $511.6M at Sep 30, 2022.
- Cash runway expected into 2025; operating cash burn $219.8M for nine months ended Sep 30, 2022.
- SC291 (allogeneic CAR T) IND filing on track for 2022 with clinical data expected in 2023.
- SG295 (in vivo CAR T) IND filing delayed to 2023 to incorporate second-generation process with 50X potency improvement.
- SC276 IND on track for 2023; SC451 (type 1 diabetes cell therapy) IND expected in 2024 with data in 2024.

## SEC filing metadata
- accession: 0001564590-22-036367
- form_type: 8-K
- ticker: SANA
- cik: 0001770121
- company_name: Sana Biotechnology, Inc.
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770121/000156459022036367/0001564590-22-036367-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770121/000156459022036367/sana-8k_20221102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-036367
- JSON: https://secwatch.observer/filing/0001564590-22-036367.json
- Plain text: https://secwatch.observer/filing/0001564590-22-036367.txt

## Key facts
- Earnings Releases
  Sana Biotechnology, Inc. reported financial results for the quarter and year ended September 30, 2022.
  - Period: the quarter and year ended September 30, 2022
  - Result: reported results
  source text: On November 2, 2022, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770121/000156459022036367/0001564590-22-036367-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.